Argireline vs Palmitoyl Tetrapeptide-7
A side-by-side research comparison of Argireline and Palmitoyl Tetrapeptide-7 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Argireline | Palmitoyl Tetrapeptide-7 |
|---|---|---|
| Full name | Argireline (Acetyl Hexapeptide-3) | Palmitoyl Tetrapeptide-7 (Pal-GQPR) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Competes with SNAP-25 for position in SNARE complex, partially inhibiting vesicle docking and neurotransmitter release, reducing muscle contraction intensity. | Inhibits IL-6 release from keratinocytes and reduces inflammation-mediated MMP activation, preserving existing collagen while complementing Pal-GHK collagen building. |
| Molecular weight | 889 Da | 693 Da |
| Half-life | 8-12 hours (topical) | 8-12 hours (topical) |
| Bioavailability | Moderate (topical) | Good (topical) |
| Typical dose | 5-10% solution | 2-4% in formulation |
| Frequency | 2x daily | 1-2x daily |
| Route | Topical | Topical |
Argireline reported benefits
- Reduces expression wrinkles up to 30%
- Non-invasive Botox alternative
- Prevents new wrinkle formation
- No muscle paralysis
- Stackable with other peptides
Palmitoyl Tetrapeptide-7 reported benefits
- Anti-inflammatory (skin)
- Reduces IL-6
- Prevents collagen degradation
- Combats inflammaging
Related comparisons
Research and educational reference only. Not medical advice.